Annina Schmid Dissects Nerve Disorders

A background in physiotherapy helps the Oxford-based researcher mix basic science with clinical work to better understand pain stemming from nerve compression.

Jan 1, 2018
Catherine Offord


As a physiotherapist at University Hospital Zurich in the mid-2000s, Annina Schmid often encountered people with chronic pain. “My interest in research got sparked while I was seeing my patients,” she says. “It was very difficult to treat them, or to understand why pain persists in some people, while it doesn’t even occur in others.”

Schmid, who grew up in Switzerland, had earned her master’s degree in clinical physiotherapy in 2005 at Curtin University in Perth, Australia, and she was keen to return down under. In 2008, she secured an Endeavour Europe Scholarship from the Australian Government and moved to the University of Queensland in Brisbane for a PhD in neuroscience.

“She’s very motivated,” says Schmid’s colleague and collaborator Brigitte Tampin, a musculoskeletal physiotherapist at Curtin University and at Osnabrück University of Applied Sciences in Germany. Tampin adds that Schmid’s physiotherapy background was an asset for her PhD work and beyond. “She can think as a clinician and as a researcher.”

For her PhD, Schmid focused on animal models of mild nerve compression, also called entrapment neuropathy, in which pressure on nerve fibers—from bone, for example—can cause pain and loss of motor function. Using a tube to compress the sciatic nerves of rats, Schmid was able to replicate not only local symptoms seen in humans, but also inflammation at distant sites, a possible explanation for why patients often report pain in other parts of the body.1

By the time she earned her doctorate in 2011, Schmid says she was “hooked” on research. During a subsequent internship with Claudia Sommer at the University of Würzburg, Germany, Schmid processed skin biopsies from patients with the pain syndrome fibromyalgia, and found degeneration in small nerve fibers—a finding she says helped shape her future focus.2

Shortly afterward, Schmid began a postdoc with neurobiologist David Bennett at the University of Oxford’s Nuffield Department of Clinical Neurosciences (NDCN). “She’s always been a joy to work with,” says Bennett. “She’s got a nice way of thinking about interesting and important questions in neuropathic pain.”

Working on patients with carpal tunnel syndrome—a common entrapment neuropathy affecting the wrist—Schmid described reductions in small fiber density and showed that changes in nerve structure occurred even far away from the site of compression.3

In 2015, Schmid won an early career research grant from the International Association for the Study of Pain. Now an associate professor at NDCN, she continues to collaborate with Bennett to study nerve regeneration following compression. She also practices physiotherapy part-time and shares her expertise with students. “Her teaching is always very well received,” says Bennett. “She’s a very good communicator.”

Beyond the University of Oxford, Schmid teaches at Oxford Brookes University and leads international courses for physiotherapists with Tampin. “I’m quite passionate about trying to translate findings from research to clinicians,” Schmid says. “Physiotherapy is a profession that’s still very close to my heart.” 


  1. A.B. Schmid et al., “Local and remote immune-mediated inflammation after mild peripheral nerve compression in rats,” J Neuropathol Exp Neurol, 72:662-80, 2013. (Cited 32 times)
  2. N. Üçeyler et al., “Small fibre pathology in patients with fibromyalgia syndrome,” Brain, 136:1857-67, 2013. (Cited 210 times)
  3. A.B. Schmid et al., “The relationship of nerve fibre pathology to sensory function in entrapment neuropathy,” Brain, 137:3186-99, 2014. (Cited 23 times)

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.